Document Detail

Five-year evaluation of the Carpentier-Edwards porcine bioprosthesis.
MedLine Citation:
PMID:  6381888     Owner:  NLM     Status:  MEDLINE    
The Carpentier-Edwards porcine bioprosthesis compares favorably to other value substitutes, with a low incidence of valve-related complications after up to 6 years' follow-up. From April, 1976, to February, 1978, 397 prostheses were implanted in 355 patients at the University of British Columbia and the Montreal Heart Institute: aortic valve replacement (AVR), 155; mitral valve replacement (MVR), 154; tricuspid valve replacement (TVR), five; multiple replacement (MR), 41 patients. Previous cardiac operations had been performed in 58 patients (16.3%). Concomitant cardiac procedures, including myocardial revascularization, were performed in 66 patients (18.5%). The 30 day mortality was 8.7% (31 patients (AVR, 4.5%; MVR 9.0%; TVR 20%; MR 21.9%). The cumulative follow-up was 1,367 patient-years (range 6 to 81 months, mean 51 months). The late mortality is 3.9% per patient-year (AVR 3.4%, MVR 3.6%, MR 6.3%). The long-term valve-related complication rates (expressed as percent per patient-year and number of events) are as follows; thromboembolism (AVR 1.1 [seven], MVR 1.7 [10], MR 3.2 [four]; prosthetic valve endocarditis (AVR 0.6 [four], MVR 0.3 [two], MR 1.6 [two]); primary tissue failure (AVR 0.16 [one], MVR 1.0 [six], MR 1.6 [two]); anticoagulant-related hemorrhage 0.07 (one); and reoperation (AVR 0.48 [three], MVR 1.32 [eight], MR 2.4 [three]). Actuarial survival rates at 6 years, including operative deaths, are as follows: AVR 81.4% +/- 5.6%, MVR 70.0% +/- 6.7%, and MR 52.1% +/- 12.5%. The overall survival rate was 74.0% +/- 4.5% at 6 years. The freedom from all valve-related complications at 72 months was 83.9% +/- 4.8%. The freedom from valve-related death was 97.3% +/- 1.8% at 72 months. The freedom from valve-related death and reoperation at 72 months was 91.5% +/- 3.8%, and the freedom from reoperation alone was 93.4% +/- 3.5%. There were no deaths due to reoperation for primary tissue failure. Performance to date with the Carpentier-Edwards porcine bioprosthesis has been excellent, with an evaluation interval extending from 60 to 81 months.
W R Jamieson; L C Pelletier; M T Janusz; B R Chaitman; F O Tyers; R T Miyagishima
Related Documents :
17126558 - Six-month outcome of transapical transcatheter aortic valve implantation in the initial...
8000588 - Long-term clinical outcome with small size standard st jude medical valves implanted in...
20019148 - Relapse of enterococcal prosthetic valve endocarditis with aortic root abscess followin...
8267458 - Surgical management of aortic valve injury after nonpenetrating trauma.
8076488 - Perineal wound management after abdominoperineal rectal excision for carcinoma with uns...
15693788 - Cost-effectiveness of rituximab (mabthera) in diffuse large b-cell lymphoma in the neth...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Journal of thoracic and cardiovascular surgery     Volume:  88     ISSN:  0022-5223     ISO Abbreviation:  J. Thorac. Cardiovasc. Surg.     Publication Date:  1984 Sep 
Date Detail:
Created Date:  1984-10-04     Completed Date:  1984-10-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0376343     Medline TA:  J Thorac Cardiovasc Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  324-33     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bioprosthesis* / adverse effects,  mortality
Endocarditis / etiology
Evaluation Studies as Topic
Heart Valve Prosthesis* / adverse effects,  mortality
Middle Aged
Postoperative Complications / mortality
Thromboembolism / etiology

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fifteen years of study of psychoactive snuffs of South America: 1967-1982--a review.
Next Document:  Cardiac tumors. Clinical spectrum and prognosis of lesions other than classical benign myxoma in 20 ...